Gluconeogenesis

Introduction

When dietary glucose is unavailable, some tissues still require a supply of blood glucose. The liver, and during prolonged fasting the kidney, can produce glucose from lactate, glycerol and suitable amino-acid carbon skeletons. This pathway is gluconeogenesis. It shares several reversible reactions with glycolysis, but it cannot simply run every glycolytic reaction backward: three glycolytic steps are so favourable in the forward direction that distinct bypass reactions are needed.

Core explanation

Glycolysis converts glucose to two pyruvates, generating a modest amount of ATP. Gluconeogenesis makes glucose from two three-carbon inputs at a net energy cost. The first major bypass replaces pyruvate kinase. Mitochondrial pyruvate carboxylase uses ATP, bicarbonate and a biotin cofactor to convert pyruvate into oxaloacetate. Phosphoenolpyruvate carboxykinase, PEPCK, then uses GTP to convert oxaloacetate to phosphoenolpyruvate, PEP, with decarboxylation. The combined carboxylation–decarboxylation sequence helps drive formation of the high-energy PEP intermediate. Oxaloacetate itself cannot freely cross the inner mitochondrial membrane, so its carbon may be transferred as malate or another suitable intermediate when needed.

Most reactions from PEP toward fructose-1,6-bisphosphate use the reversible enzymes of glycolysis in the opposite direction. Two three-carbon chains are ultimately joined to build a six-carbon sugar. The second bypass replaces phosphofructokinase-1: fructose-1,6-bisphosphatase hydrolyses fructose-1,6-bisphosphate to fructose-6-phosphate plus inorganic phosphate. It does not regenerate ATP. The third bypass replaces hexokinase or glucokinase: glucose-6-phosphatase hydrolyses glucose-6-phosphate to free glucose, again releasing inorganic phosphate. Its presence in glucose-exporting tissues helps distinguish them from muscle, which lacks a comparable capacity to release significant free glucose from its glycogen stores.

From two pyruvates, the conventional net accounting consumes four ATP and two GTP, plus two NADH, to produce one glucose. This energy investment makes the reverse overall route thermodynamically feasible under physiological conditions. It would be wasteful if glycolysis and gluconeogenesis ran strongly in opposite directions simultaneously. Reciprocal regulation therefore controls their distinct irreversible steps: high fructose-2,6-bisphosphate promotes PFK-1 and suppresses fructose-1,6-bisphosphatase, favouring glycolysis; a fall in this regulator supports the opposite shift. Acetyl-CoA activates pyruvate carboxylase, linking gluconeogenic capacity to fuel availability.

Different substrates enter at different points. Lactate can be oxidised to pyruvate, as in the Cori cycle between muscle or red blood cells and liver. Glycerol from triacylglycerol can enter as a triose-phosphate precursor. Many glucogenic amino acids supply pyruvate or citric-acid-cycle intermediates. In humans, the two carbons of acetyl-CoA from even-chain fatty acids do not give net glucose through the citric acid cycle because those carbons are balanced by decarboxylation and pyruvate dehydrogenase does not run backward. Glycerol from fats is a different matter.

Step-by-step reasoning

Mark the three essentially irreversible glycolytic steps: pyruvate kinase, PFK-1 and hexokinase/glucokinase. Replace each with its gluconeogenic bypass, then use reversible shared steps between them. Count ATP, GTP and NADH for two pyruvates rather than one, because one glucose needs six carbons. Finally identify the tissue and the starting substrate before concluding that glucose can enter blood.

Visual explanation

Draw glycolysis downward and gluconeogenesis upward on parallel arrows. At the three blocked reverse steps, draw side paths through pyruvate carboxylase plus PEPCK, fructose-1,6-bisphosphatase and glucose-6-phosphatase. Label energy consumption beside the first bypass and the shared reverse steps. A pathway map makes clear that gluconeogenesis is a related route with different enzymes, not a literal reversal.

Real-world analogy

A steep one-way road may be easy to descend but impossible to climb by simply reversing a vehicle's motion. A return journey needs ramps that go around the steepest drops and spends fuel doing so. The analogy captures why strongly favourable glycolytic steps need bypasses, although real enzymes control chemical free energy rather than traffic direction.

Real-world example

During a fast, liver cells can take up lactate released by red blood cells and convert its carbon back to glucose. Red blood cells depend on glycolysis because they lack mitochondria; the liver spends energy to help sustain their glucose supply. This carbon cycle is not an energy-producing perpetual loop. The energetic cost is paid by fuel oxidation elsewhere in the body.

Why?

Why are hydrolytic phosphatases used for the two sugar-phosphate bypasses? Removing phosphate from fructose-1,6-bisphosphate and glucose-6-phosphate without making ATP provides a favourable route that differs from simply reversing kinase reactions. This avoids a thermodynamic bottleneck and creates independent regulatory points so glycolysis and glucose synthesis can be coordinated.

Common misconception

Gluconeogenesis is not simply glycogen breakdown; it assembles new glucose from noncarbohydrate carbon. Nor does every fatty-acid carbon become glucose in humans. Even-chain fatty-acid beta-oxidation produces acetyl-CoA, which has no net route to glucose through the ordinary human citric acid cycle. The glycerol backbone of triacylglycerol can contribute.

Worked example

Two lactate molecules first become two pyruvates through lactate dehydrogenase. To form one glucose from those two pyruvates, the canonical gluconeogenic reactions use four ATP and two GTP; the pyruvate-to-PEP bypass alone uses two ATP and two GTP for the pair. This energy accounting explains why liver fuel oxidation is needed to sustain glucose export rather than gaining ATP from the carbon cycle itself.

Quick check

1. Which gluconeogenic enzyme bypasses PFK-1? Answer: Fructose-1,6-bisphosphatase hydrolyses fructose-1,6-bisphosphate to fructose-6-phosphate and Pi, avoiding reversal of the ATP-driven PFK-1 step.

Exam focus

Name all three bypasses and their corresponding glycolytic steps. Distinguish pyruvate carboxylase from PEPCK and mention biotin, ATP and GTP in the correct places. Explain regulation using fructose-2,6-bisphosphate rather than saying only that the pathways are opposites.

Advanced insight

The redox requirement depends on the starting substrate and where it enters. Lactate oxidation to pyruvate generates cytosolic NADH, which can supply the later gluconeogenic glyceraldehyde-3-phosphate dehydrogenase reaction. Starting directly from pyruvate requires that cytosolic reducing equivalents be provided by another route. Thus a single net energy equation is useful but does not capture every compartment-specific transfer.

Summary

Gluconeogenesis maintains glucose supply by building sugar from lactate, glycerol and glucogenic carbon. It bypasses pyruvate kinase with pyruvate carboxylase and PEPCK, PFK-1 with fructose-1,6-bisphosphatase and hexokinase with glucose-6-phosphatase. Energy consumption and reciprocal regulation distinguish it from merely reversing glycolysis.

Practice questions

1. Why can liver release glucose from glucose-6-phosphate while skeletal muscle mainly retains its glucose-derived carbon? Answer: Liver has glucose-6-phosphatase for dephosphorylation and export of free glucose. Skeletal muscle lacks a comparable capacity and uses its glycogen mainly for its own ATP production. 2. What is the function of pyruvate carboxylase in the pyruvate-to-PEP bypass? Answer: It uses ATP and biotin to carboxylate pyruvate into oxaloacetate. PEPCK subsequently decarboxylates and phosphorylates that intermediate to form PEP. 3. Can carbon from the glycerol part of a triacylglycerol support net glucose synthesis? Answer: Yes. Glycerol can enter gluconeogenesis through a triose-phosphate route. This differs from the even-chain fatty-acid portion, whose acetyl-CoA does not yield net glucose in humans.